AIMS: To investigate whether Oct4, Sox2 and Nanog, three core regulatory factors maintaining pluripotency and self-renewal of embryonic stem cells (ESCs), are coexpressed in human gliomas, and whether their expression might be linked to carcinogenesis and the formation of cancer stem cells (CSCs). METHODS AND RESULTS: Forty cases of human glioma were examined. The expression of Oct4, Sox2 and Nanog was analysed by immunohistochemistry, reverse transcription polymerase chain reaction and western blot. We found a positive correlation between the expression levels of Oct4, Sox2 and Nanog and tumour malignancy. Immunohistochemistry showed that Oct4 and Nanog were expressed in both the nuclei and the cytoplasm of glioma cells, whereas Sox2 was expressed only in the nuclei. Double immunofluorescence staining revealed that a majority of Oct4-positive cells coexpressed Sox2 and Nanog. More than 50% of Oct4-positive cells coexpressed the putative CSC markers CD133 and Nestin. Moreover, some cells exhibited Oct4 and Nanog immunoexpression in the cytoplasm, but the frequency of positive cells did not correlate with tumour malignancy. CONCLUSIONS: The present findings suggest that ESC-associated pathways are activated in human gliomas and that these may be involved in glioma progression, a role that is distinct from that in ESCs. 2011 Blackwell Publishing Limited.
AIMS: To investigate whether Oct4, Sox2 and Nanog, three core regulatory factors maintaining pluripotency and self-renewal of embryonic stem cells (ESCs), are coexpressed in humangliomas, and whether their expression might be linked to carcinogenesis and the formation of cancer stem cells (CSCs). METHODS AND RESULTS: Forty cases of humanglioma were examined. The expression of Oct4, Sox2 and Nanog was analysed by immunohistochemistry, reverse transcription polymerase chain reaction and western blot. We found a positive correlation between the expression levels of Oct4, Sox2 and Nanog and tumour malignancy. Immunohistochemistry showed that Oct4 and Nanog were expressed in both the nuclei and the cytoplasm of glioma cells, whereas Sox2 was expressed only in the nuclei. Double immunofluorescence staining revealed that a majority of Oct4-positive cells coexpressed Sox2 and Nanog. More than 50% of Oct4-positive cells coexpressed the putative CSC markers CD133 and Nestin. Moreover, some cells exhibited Oct4 and Nanog immunoexpression in the cytoplasm, but the frequency of positive cells did not correlate with tumour malignancy. CONCLUSIONS: The present findings suggest that ESC-associated pathways are activated in humangliomas and that these may be involved in glioma progression, a role that is distinct from that in ESCs. 2011 Blackwell Publishing Limited.
Authors: G Xi; E Hayes; R Lewis; S Ichi; B Mania-Farnell; K Shim; T Takao; E Allender; C S Mayanil; T Tomita Journal: Oncogene Date: 2015-03-30 Impact factor: 9.867
Authors: Lei Zhang; Yong Yan; Ying Jiang; Jun Qian; Lei Jiang; Guohan Hu; Yicheng Lu; Chun Luo Journal: Oncol Lett Date: 2017-08-04 Impact factor: 2.967
Authors: Eman A Toraih; Manal S Fawzy; Abdullah I El-Falouji; Elham O Hamed; Nader A Nemr; Mohammad H Hussein; Noha M Abd El Fadeal Journal: Mol Med Date: 2016-09-12 Impact factor: 6.354